Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel

PURPOSE: We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-sensitive prostate cancer. METHODS...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Harshman, Lauren C., Chen, Yu-Hui, Liu, Glenn, Carducci, Michael A., Jarrard, David, Dreicer, Robert, Hahn, Noah, Garcia, Jorge A., Hussain, Maha, Shevrin, Daniel, Eisenberger, Mario, Kohli, Manish, Plimack, Elizabeth R., Cooney, Matthew, Vogelzang, Nicholas J., Picus, Joel, Dipaola, Robert, Sweeney, Christopher J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805480/
https://ncbi.nlm.nih.gov/pubmed/29261442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.3921
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares